Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening
- PMID: 32602898
- PMCID: PMC7566359
- DOI: 10.1093/jnci/djaa092
Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7566359/bin/djaa092f1.gif)
Comment in
-
Response to Lehrer and Rheinstein.J Natl Cancer Inst. 2020 Oct 1;112(10):1069-1070. doi: 10.1093/jnci/djaa093. J Natl Cancer Inst. 2020. PMID: 32602890 Free PMC article. No abstract available.
Comment on
-
Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.J Natl Cancer Inst. 2021 Jan 4;113(1):64-71. doi: 10.1093/jnci/djaa068. J Natl Cancer Inst. 2021. PMID: 32432713 Free PMC article.
Similar articles
-
Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.Eur Urol. 2022 Mar;81(3):313. doi: 10.1016/j.eururo.2021.12.028. Epub 2022 Jan 10. Eur Urol. 2022. PMID: 35027257 No abstract available.
-
New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough.Einstein (Sao Paulo). 2017 Jul-Sep;15(3):7-10. doi: 10.1590/S1679-45082017ED4151. Einstein (Sao Paulo). 2017. PMID: 29091165 Free PMC article. No abstract available.
-
Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.Cancer. 2018 Jan 1;124(1):11-12. doi: 10.1002/cncr.31180. Cancer. 2018. PMID: 29251768 No abstract available.
-
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
-
Prostate Cancer Screening and the Associated Controversy.Surg Clin North Am. 2015 Oct;95(5):1023-39. doi: 10.1016/j.suc.2015.05.001. Epub 2015 Jun 23. Surg Clin North Am. 2015. PMID: 26315521 Review.
Cited by
-
Response to Lehrer and Rheinstein.J Natl Cancer Inst. 2020 Oct 1;112(10):1069-1070. doi: 10.1093/jnci/djaa093. J Natl Cancer Inst. 2020. PMID: 32602890 Free PMC article. No abstract available.
References
-
- Lehrer SP. Obesity and aggressive prostate cancer. Cancer. 2020;126(10):2319–2319. - PubMed
-
- Horner MJ, Ries LAG, Krapcho M, et al.SEER Cancer Statistics Review, 1975-2006, Bethesda, MD: National Cancer Institute; 2009.
-
- Cho H, Howlader N, Mariotto AB, et al. Estimating relative survival for cancer patients from the SEER program using expected rates based on Ederer I versus Ederer II method. Surveillance Research Program, NCI. 2011;2011(1):1–17.